Oliden 2012.

Methods	judgementCountry: Study design: Prospective randomised uncontrolled parallel‐group randomised trial Duration of study: not reported Duration of follow‐up: 24 weeks
Participants	Country: Argentina Setting: single centre Inclusion criteria: kidney transplant recipients; eGFR < 60 mL/min; secondary hyperparathyroidism Number: treatment group (6); control group (6) Mean age ± SD (years): treatment group (57.5 ± 8); control group (52.3 ± 6) Sex (M/F): not reported Exclusion criteria: GFR > 60 mL/min; PTH > 110 pg/mL; corrected calcium >10.5 mg/dL; serum phosphorus > 5.5 mg/dL
Interventions	Treatment group Paricalcitol (oral): uncertain dose (error in abstract) Control group Calcitriol (oral): 0.25 mg/d Co‐interventions Not reported
Outcomes	PTH
Notes	Abstract‐only publication; full‐text publication not identified Funding source: not reported Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients included in outcome assessment at 24 weeks
Selective reporting (reporting bias)	High risk	Patient important outcomes were not all reported in systematic way
Other bias	Unclear risk	Insufficient information to permit judgement